| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 4
| Issue : 3 | Page : 67-74 |
|
|
Cardiovascular complications of COVID-19
Joana Brito1, Beatriz Valente Silva1, Pedro Alves da Silva1, Nuno Cortez-Dias1, Doroteia Silva2, João R Agostinho1, Tatiana Guimar1, Dulce Brito1, Fausto J Pinto1
1 Department of Heart and Vessels, Division of Cardiology, Centro Hospitalar Universitário Lisboa Norte, Cardiovascular Centre of Universidade de Lisboa (CCUL), Lisbon School of Medicine, Universidade de Lisboa, Lisbon, Portugal
2 Department of Heart and Vessels, Division of Cardiology, Centro Hospitalar Universitário Lisboa Norte, Cardiovascular Centre of Universidade de Lisboa (CCUL), Lisbon School of Medicine, Universidade de Lisboa; Department of Intensive Care, Centro Hospitalar Universitário Lisboa Norte, Santa Maria University Hospital, Lisbon, Portugal
Correspondence Address:
Prof. Fausto J Pinto
Department of Heart and Vessels, Division of Cardiology, Santa Maria University Hospital, Av. Prof. Egas Moniz, 1649 028, Lisboa
Portugal
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/hm.hm_28_20
|
|
|
Coronavirus disease 19 (COVID-19) has rapidly expanded to a global pandemic, resulting in significant morbidity and mortality. Even though predictors of infection remain unclear, age and preexisting cardiovascular conditions have been clearly identified as predictors of adverse outcomes and higher fatality rates. Since the virus infects host cells through angiotensin-converting enzyme 2 receptors, a key player in the renin-angiotensin-aldosterone system, the interaction between the cardiovascular system and the progression of COVID-19 is nowadays a focus of huge interest. In this review, the authors analyze the available and very recent evidence on the risk factors and mechanisms of the most relevant cardiovascular complications associated with COVID-19, including acute cardiac injury, myocarditis, stress-cardiomyopathy, ischemic myocardial injury, cytokine release syndrome, thrombotic disease, cardiac arrhythmias, heart failure, and cardiogenic shock. Finally, we discuss the cardiovascular impact of the therapies under investigation for COVID-19 treatment.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
